Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Scrip 100 Analysis: Impairment, Youth Boost R&D Spending

Spending on R&D increased substantially in 2016; but the picture is complicated and more than half of the increase is due to accountancy updates following drug program failures, one large company's commitment to new projects, and young companies fuelled by generous financial markets.

Scrip 100 Research and Development Strategies Sales & Earnings

Global CRISPR Revolution Gathers Pace, Raising Hopes – And Concerns

CRISPR technology was invented just five years ago but is so accurate, versatile, easy to use, and inexpensive that it has spread quickly through biology laboratories, giving researchers new tools to interrogate biology and make precise alterations to an organism’s genetic material, offering its potential use in a wide array of therapies.

Scrip 100 Platform Technologies Research and Development Strategies

Gene Editing: A Powerful, Growing Modality In Regenerative Medicine

Regenerative medicine has made advances in recent years to emerge as one of the key fields with a chance of addressing, and even curing, diseases that until now had few or no treatment options.

Research and Development Strategies Scrip 100 Regenerative Medicine

Will J&J TRANSFORM Esketamine Into A Viable Depression Treatment?

In early 2018 Johnson & Johnson is expecting to announce the first data from its long-awaited pivotal clinical trial program for esketamine in treatment-resistant depression; a successful result will open a lucrative commercial opportunity for J&J and give the wider depression market a new direction for growth.

Scrip 100 Neurology Market Intelligence

Interview: Joerg Moeller, Bayer Development Chief, On R&D Consolidation

Scrip caught up with Joerg Moeller, head of development at Bayer Pharmaceuticals, during the company's annual media day. Soon to take leadership of the German group's entire R&D organization, he talked about Bayer's R&D strategy and how the pharma industry will need to work with other healthcare stakeholders more collaboratively.

Research and Development Strategies Leadership Innovation